Our findings demonstrated that treatment of glioma cells with lestaurtinib not affect Bax, Bad, Bcl‐2 and Bcl‐xl levels, but promoted Bid activation (Figure 3C,D). Here, BCL2L1 is linked to central nervous system cancer.